At Astellas, the health and well-being of our employees, patients and communities is of high importance. 

We continue to monitor the global COVID-19 situation. The supply, manufacturing and distribution of Astellas products in Europe, Canada and Australia is not impacted, and patients will continue to be able to receive all approved medicines, without interruption related to COVID-19.

As the COVID-19 situation continues to evolve, Astellas remains focused on protecting our ability to manufacture and supply safe and effective medicines for patients who need them.



NON_2020_0032_APE. March 2020.


The Astellas EST-C Communications team
will respond to emails from journalists.
For general media enquiries,
please email [email protected].